The administration of probiotics in mothers during pregnancy and after birth has shown several benefits on babies’ health, including the improvement of infant colic. For instance, Limosilactobacillus reuteri (basonym “Lactobacillus reuteri”) LR 92 has demonstrated to positively improve infant colic in the first months of life.
What is infant colic?
Infant colic is a condition affecting about 20% infants younger than 3 months old, and is often described as “excessive crying”. The aetiology is unclear but likely related to psychological and physiological causes.
In children, colic leads to sleeping problems and it can also cause allergies, migraine, attention deficit and hyperactivity as long-term effects.
Moreover, infant colic may also cause sleeping disorders and depression in parents due to the continuous crying and sleepless nights [1-2].
Probiotic LR 92 and babies health: clinical evidence
A randomized, double-blind, placebo-controlled trial was conducted on 145 women (18-49 years old) that consumed capsules of LR 92 (108 CFU/day) or a placebo during the last 4 weeks pregnancy [3]. The babies were then monitored for 4-5 months and:
- Babies from mothers who received placebo were 2.36 times more likely to have colic
- The frequency and severity of colic were significantly lower in the intervention group
- LR 92 intake appeared to be especially beneficial for babies born by C- section
Proposed mechanisms of action
Although a full understanding of how perinatal administration of probiotics improves infant colic is still lacking, several mechanisms have been identified [4-8]:
- increase levels of anti-inflammatory mediators such as IL-10 and TGF-β in breast milk, which in turn stimulate the gut development and IgA secretion, control inflammation and improve gastrointestinal function
- improve gut barrier function by stabilizing tight junctions and mucin production
- promote the production of gamma-aminobutyric acid (GABA), which is the major inhibitory neurotransmitter, and influences behaviour
- modulate gut microbiota development
___________________________________________________
1. Zeevenhooven J et al (2018). Infant colic: mechanisms and management. Nat Rev Gastroenterol Hepatol. 15(8):479-496
2. https://www.mayoclinic.org/diseases-conditions/colic/symptoms-causes/syc-20371074
3. Pourmirzaiee MA et al. (2020) The efficacy of the prenatal administration of Lactobacillus reuteri LR92 DSM 26866 on the prevention of infantile colic: a randomized control trial. Eur J Pediatr 179, 1619–1626.
4. Sung V et al (2018) Lactobacillus reuteri to Treat Infant Colic: A Meta-analysis. Pediatrics 141(1):e20171811
5. Sohn K and Underwood MA (2017) Prenatal and postnatal administration of prebiotics and probiotics. Semin Fetal Neonatal Med. 22(5): 284–289.
6. Sung V, et al. (2012) Probiotics to improve outcomes of colic in the community: protocol for the Baby Biotics randomised controlled trial. BMC Pediatr. 12:135
7. Baldassarre ME et al (2018) Rationale of Probiotic Supplementation during Pregnancy and Neonatal Period. Nutrients 6;10(11):1693.
8. Grze?kowiak ? et al. (2012) The impact of perinatal probiotic intervention on gut microbiota: double-blind placebo-controlled trials in Finland and Germany. Anaerobe. 2012;18(1):7?13.
Latest News
An important regulatory goal has been achieved with the conclusion reached by an independent expert panel for the self-affirmed GRAS (Generally Recognized as Safe) determination of our postbiotic CRL1505® HI.
“Survivability of probiotic CA15 strain with and without fluconazole co-administration and its effect on gut microbiota and metabolome through SHIME® model” is the title of the study that has been
GRAS (Generally Recognised as Safe) is a designation by the US Food and Drug Administration (FDA) that indicates that a substance is considered safe based on expert consensus or a
Brisbane, 8 January 2025 Sacco System Australia, a leader in innovative probiotic and postbiotic solutions, is proud to announce that L. rhamnosus CRL 1505 HI (heat-inactivated) and Lactobacillus acidophilus LA1
Our commitment to sustainability: a review of an evolving journey We are proud to present the fifth edition of our Sustainability Report, an opportunity to reflect on the milestones achieved
Today in the presence of Luna Angelini Marinucci, from 2022 the Consul of Italy in Brisbane, with territorial jurisdiction over the State of Queensland and over the Northern Territory the
At Sacco System we have always put Sustainability at the very core of our activities and our commitment, which is why we are proud that our companies Caglificio Clerici, Sacco
Indianapolis, Ind., and Yeerongpilly, Queensland, Australia, March 13, 2024 – List Biotherapeutics, Inc. (List Bio) and Sacco System Australia Pty Ltd (Sacco) today announced a lead share agreement to introduce
Sacco System is the international biotechnological company dedicated to the food, nutraceutical, and pharmaceutical industries, based on tradition, expertise, research, and innovation which sells and distributes its ingredients in more
We are proud to announce that Sacco System has made a significant donation in support of Action4Diabetes (A4D), mission—a UK-based charity committed to ensuring free access to crucial medical supplies,
This year too, SACCO SYSTEM proudly participates in the Deploy Your Talents (DYT) project, promoted by the Fondazione Sodalitas, with the patronage of the Municipality of Milan and in collaboration
Sacco System is pleased to announce that the new website ingredients.saccosystem.com is now online. INgredients is a project launched in 2020 with the aim of making the hidden world of